Ankylose This! Living with Ankylosing Spondylitis

Saturday, April 14, 2007

Arcoxia approval rejected by FDA panel

More bad news for Merck: an FDA panel voted against approving Arcoxia (etoricoxib), a COX-2 inhibitor touted as a successor to Vioxx: "Expressing concern over the cardiac safety of Arcoxia, the FDA panel voted 20 to 1, opposing the approval of the drug." The FDA's final decision comes on April 27.

Previously: Arcoxia better than naproxen?

Labels: , ,